Search the Newsreel

Acciones de Novo Nordisk caen tras una mejora de previsiones menor a la esperada

‘Arrogance kills’: Novo chief injects risk-taking into Ozempic maker

One year since becoming Novo Nordisk’s chief executive, Mike Doustdar is betting on the “phenomenal” sales of its weight-loss pill, new PREMIUM Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access …

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is scheduled to report its second-quarter 2026 results on Aug. 5, 2026, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $11.27 billion, while the same for earnings is pinned at 82 …

Novo Nordisk (NVO) Trial Setback Hits Sentiment, Is The Stock Still Cheap?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Trial setback puts focus on Novo Nordisk stock Novo Nordisk (NYSE:NVO) is under fresh scrutiny after the ZEUS phase 3 trial for heart drug candidate …

Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent Setbacks

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk stock has slipped over the past year and is down 36.4% over three years, yet the valuation checks still lean supportive, which …

Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial

Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Novo Nordisk’s Heart Drug Suffers a Major Setback. What It Means for the Stock.

The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge. Continue Reading

Weight Loss Drug Stocks Slump. What Ozempic Maker Novo Nordisk Said.

Weight loss drug stock leaders slumped on Friday amid updates and ahead of earnings. NVO stock sank under a buy point on trial results. LLY stock dived below support with earnings due next week. Updating the closely watched ZEUS phase 3 clinical trial, Denmark's …

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

European stock markets closed mixed in Friday trading with the Stoxx 600 easing 0.1%, Germany's DAX adding 0.1%, the UK's FTSE 100 shedding 0.3%, France's CAC rising 0.3%, and the Swiss Market Index down 0.3%.In economic news, the Eurozone consumer price index (CPI) rose …

Novo Nordisk Suffers Another Pipeline Setback

This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials), the Danish pharmaceutical company, saw its shares fall sharply Friday after a late-stage trial of its experimental heart medicine failed to meet its primary endpoint. Warning! GuruFocus has detected 4 Warning Sign with NVO. …

Novo Nordisk Stock Falls 7% as ZEUS Trial Fails

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) fell 7.42% in Copenhagen after reporting that ziltivekimab failed to reduce major adverse cardiovascular events in the ZEUS phase 3 trial. The hazard ratio against placebo was 0.99, meaning no measurable difference, with a confidence …

Novo Nordisk stock tumbles 10% as key trial misses goal

Investing.com -- Novo Nordisk (NYSE: NVO) shares dropped 10% Friday after the drugmaker revealed its experimental drug, ziltivekimab, failed to cut cardiovascular risk in a late-stage clinical trial. The Danish company reported that its Phase 3 ZEUS trial showed no reduction in major adverse …

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisktoday announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive …

Novo Nordisk (CPSE:NOVO B) Is Up 5.9% After EU Wegovy Pill Approval And US Access Deal

Earlier this month, the European Commission granted marketing authorisation for Novo Nordisk's once-daily Wegovy oral pill for obesity across all EU member states, while Crux announced a collaboration with the company to expand affordable, simplified access to authentic anti-obesity medications like Wegovy for US …

Novo Nordisk (CPSE:NOVO B) Teams Up With Crux To Expand Wegovy Access

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) has partnered with Crux to expand access to anti obesity medicines such as Wegovy for employer health plans in …

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Since launch, Novo Nordisk has steadily expanded the commercial opportunity …

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

Novo Nordisk (NVO) closed at $50.96 in the latest trading session, marking a +2.6% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 1.03%, while the tech-heavy Nasdaq lost 0.22%. The …

Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight

The congestive heart failure market is expected to witness steady growth over the coming years, driven by the rising prevalence of cardiovascular diseases, an aging global population, and increasing awareness of early diagnosis and disease management. In addition, the expected launch of emerging therapies …

Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts

Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior …

Eli Lilly and Novo Nordisk Are Locked in a Legal War. Don’t Lose Sight of the Main Event.

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab. Continue Reading

Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues …

Is Novo Nordisk (CPSE:NOVO B) Fully Valued On EU Approval For Its Wegovy Pill?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member …

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab. Continue Reading

Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads

This article first appeared on GuruFocus. Danish pharmaceutical company Novo Nordisk (NVO, Financials), a maker of diabetes and obesity therapies, wants a U.S. court to issue a preliminary injunction to halt rival Eli Lilly's advertising.Novo accused Lilly of violating false advertising and unfair competition …

Lilly Targets Early 2027 Filing for Next Obesity Drug

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) fell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The …

How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly's nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo's Wegovy and Ozempic. The case …

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

MCLEAN, Va., July 23, 2026--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer …

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

In the latest close session, Novo Nordisk (NVO) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%. The drugmaker's shares have seen an …

NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now

Novo Nordisk NVO has filed a lawsuit against Eli Lilly LLY, accusing its rival of misleading high-profile U.S. advertising campaigns to promote its blockbuster injectable GLP-1 medicines, Zepbound and Mounjaro, over NVO's injectable semaglutide medicines, Wegovy and Ozempic for obesity and type II diabetes …

Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it …

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

View Comments

Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Novo Sues Lilly Over Weight-Loss Ad Claims

This article first appeared on GuruFocus. Novo Nordisk (NOVO_B) filed a lawsuit accusing Eli Lilly (NYSE:LLY) of running a "deliberately false" advertising campaign about the comparative effectiveness of their competing obesity and diabetes drugs. Novo Nordisk alleges Lilly cited outdated clinical trial data to …

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and …

Weight-loss wars: Why Novo Nordisk is suing Eli Lilly

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne. Video Transcript 00:00 Speaker A Novo Nordisk is filing …

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading